EB 8018

Drug Profile

EB 8018

Alternative Names: EB8018

Latest Information Update: 28 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Enterome
  • Class
  • Mechanism of Action Adhesion receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Crohn's disease

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Crohn's disease (In volunteers) in United Kingdom (PO) (NCT02998190)
  • 20 Apr 2016 Enterome Bioscience plans a clinical trial for Inflammatory bowel disease
  • 18 Apr 2016 Enterome Bioscience in-licenses FimH antagonists from Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top